Navigation Links
Lakewood-Amedex Inc. Appoints Marie E. Knight To Its Board Of Directors
Date:12/4/2012

SARASOTA, Fla., Dec. 4, 2012 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that it has elected Marie E. Knight to its board of directors.  Dr. Knight brings to the company her experience in both biotechnology equity research, including significant connections in the equity financing arena, and her years of high-level consulting on market intelligence in the pharmaceutical industry.  Dr. Knight will initially focus on helping the company to raise expansion capital and provide regulatory guidance as it prepares to move its Nu-2 topical anti-bacterial product to IND filing and into Phase I clinical trials in 2013. 

Dr. Knight has over 20 years in the healthcare industry, including 14 years in pharmaceutical and biotechnology equity research and as a consultant for numerous multinational pharmaceutical companies.  As a Senior Biotech Analyst at Avalon Research Group, a NASD research sell-side firm, she provided drug-pipeline analysis of publicly traded biotechnology companies and evaluation of venture capital opportunities.   She also has first-hand industry experience working at a small biotech company as a traveling developmental scientist.  In this capacity, she worked on-site for many pharmaceutical and biotech companies and collaborated with industry scientists at all stages of drug development, including basic research, pharmacokinetics, toxicology, QC, clinical testing, and manufacturing.  

She brings an international perspective as a consultant working for the last ten years with pharmaceutical teams across numerous therapeutic areas to provide actionable strategic direction.  In this role she has provided research and analysis for oncology, rheumatology, ophthalmology, infectious diseases and immunology projects, both for pre-approval and post-marketed products. 

Lakewood-Amedex's President and CEO, Steve Parkinson, commented "It is a pleasure to welcome a world-class executive of Marie Knight's standing to the board of directors.  Her hands-on intimate familiarity with the drug-development process will be invaluable in working with our team to successfully commercialize our products.  This experience brings to Lakewood-Amedex additional capabilities to navigate the regulatory environment and maximize assets to best align with future potential licensing and partnership opportunities."

Dr. Knight commented "Having researched many biotechnology companies in my time, I was greatly impressed with the breadth of the Lakewood-Amedex product portfolio and the quality of the company's science.  This sets them apart from most companies at this stage of development.  Also the management team has the right level of passion and chemistry that I can work with to help them make a great success of this very promising company.  I have already initiated communications with the FDA.  We expect to move the first product forward into the clinic rapidly and really put this company on the map."

About Lakewood-Amedex, Inc.

Lakewood-Amedex is a privately held biopharmaceutical company developing a broad portfolio of anti-infective products, including first-in-class anti-bacterial compounds, orally available nanoRNA therapeutics for acute and chronic diseases such as arthritis, inflammation, cancer, influenza, and hepatitis, and a fully human monoclonal antibody for HUS.  The Company's products and technology are covered by an extensive patent portfolio consisting of 36 granted and/or issued patents and 29 pending patent applications filed on a worldwide basis covering all major pharmaceutical markets.  The Company's lead therapeutic candidate is a novel synthetic broad spectrum anti-bacterial proven to be effective in killing a wide range of gram-positive, gram-negative, and antibiotic-resistant bacteria and is expected to enter the clinic in 2013.

This press release contains forward-looking statements that can be identified by terminology such as "expects", "potential", "suggests", "may", "will" or similar expressions.  Such forward-looking statements regarding our business, which are not historical facts, are "forward-looking statements" that involve risk and uncertainties, which could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements.  Actual results may differ materially from statements made as a result of various factors, including, but not limited to sufficiency of cash to fund the Company's planned operations, risk associated with inherent uncertainty of product research and development, risk of protecting proprietary rights and competition.  Forward-looking statements speak only as to the date they are made.  The Company does not undertake to update forward-looking statements to reflect the circumstances or events that occur after the date the forward-looking statements are made. Contacts:Steve Parkinson

Marie E. KnightPresident and CEO

DirectorLakewood-Amedex Inc.

Lakewood-Amedex, Inc.(941) 255 2515

(321) 223 3152sparkinson@lakewoodamedex.com 

mknight@lakewoodamedex.com


'/>"/>
SOURCE Lakewood-Amedex Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Amarantus Appoints Super Bowl Champion Toi Cook to Board of Advisors to Advance TBI Program
2. Regulus Appoints Victor Knopov, Ph.D. as Vice President, Pharmaceutical Development
3. CTI Appoints Monique Greer, Senior Vice President, Corporate Communications and Investor Relations
4. Novel Cancer Immune Therapy Developer Oncos Therapeutics Appoints Experienced Industry Leader Frans Wuite as President and CEO
5. Sanguine Appoints Darlene Rosario, Vice President of Regulatory Affairs & Quality at Biothera, Inc., to Clinical Advisory Board and Ethics Committee
6. Insmed Appoints 15-Year Life Sciences Industry Veteran Andrew Drechsler as Chief Financial Officer
7. ViaCyte Appoints Steve Altman to its Board of Directors
8. Northwest Biotherapeutics Appoints Pharma Industry Veteran As CEO Of German Subsidiary
9. Aushon BioSystems Appoints Martin Verhoef Chief Executive Officer
10. BioNeutral Group Appoints Mr. Mark Lowenthal as Chief Executive and President
11. BioNeutral Group Appoints A New Member to the Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):